UDK: 615.252.349:616.379-008.64-092.4

HYPOGLYCEMIC ACTIVITY OF A NOVEL GPR119 AGONIST ON A RAT MODEL WITH DEVELOPING DIABETES

D. V. Kurkin1, D. A. Bakulin1, E. V. Volotova1, M. A. Shafeev2, I. N. Tyurenkov1, E. O. Logvinova1

1Волгоградский государственный медицинский университет, кафедра фармакологии и биофармации ФУВ, 2ЗАО «Исследовательский институт химического разнообразия», г. Химки, Московская обл.

Abstract

We investigated hypoglycemic effects of ZB-16 (0,1 and 1 mg/kg, per os), a novel GPR119 receptor agonist, in rats with developing diabetes. Diabetes was induced by repeated subdiabetogenic doses (30 mg/kg/day) (i. p.) of streptozotocin. In animals with developing diabetes, ZB-16 (1 mg/kg) and sitagliptin significantly reduced the severity of hyperglycemia and improved the impaired glucose tolerance on 14 and 21 days. The therapeutic effects of GPR119 receptor agonist were comparable to those of the DPP-4 inhibitor.

Keywords

diabetes mellitus, GPR119, incretins, sitagliptin, rats.

Contacts

Куркин Денис Владимирович — к. фарм. н., ассистент кафедры фармакологии и биофармации ФУВ, Волгоградский государственный медицинский университет, e-mail: strannik986@mail.ru